Predictive Factors for Ovarian Stimulation Using a Fixed Daily Dose of 200 IU Recombinant FSH (Study 142003)(COMPLETED)(P05696) - Study Results

Study Type:	Interventional
Study Design:	Randomized, Open Label, Active Control, Parallel Assignment
Condition:	Infertility
Intervention:	Drug: Desogen/Marvelon

Participant Flow

Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups

	Description
Desogen Oral Contraceptive	Use of oral contraceptive pills prior to controlled ovarian stimulation
Non-Oral Contraceptive	No use of oral contraceptive pills prior to controlled ovarian stimulation

Participant Flow: Overall Study

	Desogen Oral Contraceptive	Non-Oral Contraceptive
STARTED	223	219
COMPLETED	195	185
NOT COMPLETED	28	34
Discontinuation: no embryo transfer	14	14
Did not receive recFSH	14	20

Baseline Characteristics

Hide Baseline Characteristics

Reporting Groups

	Description
Desogen Oral Contraceptive	Use of oral contraceptive pills prior to controlled ovarian stimulation
Non-Oral Contraceptive	No use of oral contraceptive pills prior to controlled ovarian stimulation

Baseline Measures

	Desogen Oral Contraceptive	Non-Oral Contraceptive	Total
Number of Participants [units: participants]	223	219	442
Age [units: participants]
<=18 years	0	0	0
Between 18 and 65 years	223	219	442
>=65 years	0	0	0
Gender [units: participants]
Female	223	219	442
Male	0	0	0

Outcome Measures

1. Primary:

Total Number of Oocytes [ 12 weeks ]

Show Outcome Measure 1

Serious Adverse Events

Hide Serious Adverse Events

Time Frame	No text entered.
Additional Description	No text entered.

Reporting Groups

	Description
Desogen Oral Contraceptive	Use of oral contraceptive pills prior to controlled ovarian stimulation
Non-Oral Contraceptive	No use of oral contraceptive pills prior to controlled ovarian stimulation

Serious Adverse Events

	Desogen Oral Contraceptive	Non-Oral Contraceptive
Total, serious adverse events
# participants affected / at risk	10/209 (4.78%)	9/199 (4.52%)
Gastrointestinal disorders
Colitis ulcerative ^† # participants affected / at risk # events	1/209 (0.48%) 1	0/199 (0.00%) 0
Pancreatitis ^† # participants affected / at risk # events	1/209 (0.48%) 1	0/199 (0.00%) 0
Pregnancy, puerperium and perinatal conditions
Abortion spontaneous ^† # participants affected / at risk # events	0/209 (0.00%) 0	1/199 (0.50%) 1
Antepartum haemorrhage ^† # participants affected / at risk # events	1/209 (0.48%) 1	0/199 (0.00%) 0
Ectopic pregnancy ^† # participants affected / at risk # events	2/209 (0.96%) 2	2/199 (1.01%) 2
Retroplacental haematoma ^† # participants affected / at risk # events	1/209 (0.48%) 1	1/199 (0.50%) 1
Ruptured ectopic pregnancy ^† # participants affected / at risk # events	2/209 (0.96%) 2	1/199 (0.50%) 1
Reproductive system and breast disorders
Ovarian cyst ^† # participants affected / at risk # events	0/209 (0.00%) 0	1/199 (0.50%) 1
Ovarian cyst ruptured ^† # participants affected / at risk # events	1/209 (0.48%) 1	0/199 (0.00%) 0
Ovarian hyperstimulation syndrome ^† # participants affected / at risk # events	2/209 (0.96%) 2	3/199 (1.51%) 3
Surgical and medical procedures
Abortion induced ^† # participants affected / at risk # events	1/209 (0.48%) 1	0/199 (0.00%) 0

^†	Indicates events were collected by systematic assessment.

Other Adverse Events

Show Other Adverse Events

More Information

Hide More Information

Certain Agreements:

Principal Investigators are NOT employed by the organization sponsoring the study.

There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

The agreement is:

	The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
	The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
	Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed. Restriction Description: Organon recognizes the right of the investigator(s) to publish, but all communication concerning the clinical trial must be based on data validated and released and will first be submitted to Organon for written consent, which shall not be withheld unreasonably. Organon is free to use the data for publication. The investigator(s) may be invited to be co‑author(s). In any communication concerning this clinical trial, the author(s) of this protocol will be included in the list of authors.

Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

Results Point of Contact:

Name/Title: Head, Clinical Trials Registry & Results Disclosure Group
Organization: NV Organon, part of S-P corporation
e-mail: ClinicalTrialsDisclosure@spcorp.com

No publications provided

Responsible Party:	Schering-Plough ( Head, Clinical Trials Registry & Results Disclosure Group )
Study ID Numbers:	142003, P05696
Study First Received:	October 23, 2008
Results First Received:	June 23, 2009
Last Updated:	October 2, 2009
ClinicalTrials.gov Identifier:	NCT00778999 History of Changes
Health Authority:	United States: Food and Drug Administration